Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras, et al.
Nature (2020) Vol. 585, Iss. 7826, pp. 584-587
Open Access | Times Cited: 334

Showing 1-25 of 334 citing articles:

Artificial intelligence in COVID-19 drug repurposing
Yadi Zhou, Fei Wang, Jian Tang, et al.
The Lancet Digital Health (2020) Vol. 2, Iss. 12, pp. e667-e676
Open Access | Times Cited: 535
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret, Magali Gilles, Karine Barral, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 410
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
Wesley H. Self, Matthew W. Semler, Lindsay Leither, et al.
JAMA (2020) Vol. 324, Iss. 21, pp. 2165-2165
Open Access | Times Cited: 401
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
Structures of the SARS ‐CoV‐2 nucleocapsid and their perspectives for drug design
Ya Peng, Ning Du, Yuqing Lei, et al.
The EMBO Journal (2020) Vol. 39, Iss. 20
Open Access | Times Cited: 257
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Ioannis P. Trougakos, Κimon Stamatelopoulos, Evangelos Terpos, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 240
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
Nadège Néant, Guillaume Lingas, Quentin Le Hingrat, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 8
Open Access | Times Cited: 218
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Benjamin S. Abella, Eliana L. Jolkovsky, Barbara Biney, et al.
JAMA Internal Medicine (2020) Vol. 181, Iss. 2, pp. 195-195
Open Access | Times Cited: 192
Reversed-engineered human alveolar lung-on-a-chip model
Di Huang, Tingting Liu, Junlong Liao, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 19
Open Access | Times Cited: 185
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1188-1200.e19
Open Access | Times Cited: 181
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
Chris R. Triggle, Devendra Bansal, Hong Ding, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 165
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19
Yadi Zhou, Yuan Hou, Jiayu Shen, et al.
PLoS Biology (2020) Vol. 18, Iss. 11, pp. e3000970-e3000970
Open Access | Times Cited: 159
Natural history of COVID-19 and therapeutic options
Philippe Gautret, Matthieu Million, Pierre‐André Jarrot, et al.
Expert Review of Clinical Immunology (2020) Vol. 16, Iss. 12, pp. 1159-1184
Closed Access | Times Cited: 143
Azithromycin in viral infections
Madeleine Oliver, Timothy S.C. Hinks
Reviews in Medical Virology (2020) Vol. 31, Iss. 2
Open Access | Times Cited: 142
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
Francisco J. Salguero, Andrew White, Gillian S. Slack, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 140
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
Aurélien Marc, Marion Kerioui, François Blanquart, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 126
Air-liquid interface (ALI) impact on different respiratory cell cultures
Soraia Silva, Joana Bicker, Amílcar Falcão, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 184, pp. 62-82
Open Access | Times Cited: 64
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells
Nicolas Huot, Cyril Planchais, Pierre Rosenbaum, et al.
Nature Immunology (2023) Vol. 24, Iss. 12, pp. 2068-2079
Open Access | Times Cited: 42
Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial
Radha Rajasingham, Ananta Bangdiwala, Melanie R. Nicol, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 11, pp. e835-e843
Open Access | Times Cited: 125
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
Lucy Catteau, Nicolás Dauby, Marion Montourcy, et al.
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 4, pp. 106144-106144
Open Access | Times Cited: 121
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation
Mathieu Gendrot, Julien Andréani, Manon Boxberger, et al.
Travel Medicine and Infectious Disease (2020) Vol. 37, pp. 101873-101873
Open Access | Times Cited: 99
Targeting Proteases for Treating COVID-19
Binquan Luan, Tien Huynh, Xuemei Cheng, et al.
Journal of Proteome Research (2020) Vol. 19, Iss. 11, pp. 4316-4326
Open Access | Times Cited: 94
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 12, pp. 1826-1837
Open Access | Times Cited: 91
Medicamentos e tratamentos para a Covid-19
Leonardo L. G. Ferreira, Adriano D. Andricopulo
Estudos Avançados (2020) Vol. 34, Iss. 100, pp. 7-27
Open Access | Times Cited: 90
ORF3a-Mediated Incomplete Autophagy Facilitates Severe Acute Respiratory Syndrome Coronavirus-2 Replication
Yafei Qu, Xin Wang, Yunkai Zhu, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 90
Page 1 - Next Page

Scroll to top